Forward P/S Multiple: Cidara Therapeutics (CDTX)

Corporate company logo of Cidara Therapeutics Corp (CDTX)

Cidara Therapeutics revenues rely on the licensing of early-stage assets and alliances with industry behemoths. The expected price-to-sales ratio demonstrates valuation volatility, with the 4588.60 level serving as a critical mark. Innovations are based on the creation of long-acting conjugates for systemic protection, enabling the development of unique hybrid molecules for the therapy of severe infections in immunocompromised patients.

Cidara - CDTX Market Cap to Projected Revenue (period 07/04/2022 - 08/09/2025)

Comprehensive metric breakdowns and analytics for Cidara Corp (CDTX)

- current price and projected stock value:
Stock Price Cidara Therapeutics Inc|CDTX - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization Cidara Corp|CDTX - Company Buyout Price
- issuer book value statistics:
Book Value per Share Cidara|CDTX - Accounting Capitalization|Market Capitalization to Book Value Ratio cidara.com|CDTX - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Cidara Therapeutics|CDTX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Cidara Therapeutics|CDTX - Company Aggregate Debts|Debt to Book Value Cidara Corp|CDTX - Company Long-Term Loans and Borrowings|Company Current Liabilities Cidara|Quick Ratio cidara.com
- financial results and valuation multiples details:
CDTX - Final Profit|Projected Future Earnings Cidara Therapeutics|CDTX - Market Cap to Earnings|Future Price to Earnings Cidara Therapeutics, Inc.|CDTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Cidara Corp|CDTX - Operating profit EBITDA|Earnings per share for the last twelve months Cidara|CDTX - Earnings per one share for the last 12 months|Quarterly EPS earnings growth cidara.com|CDTX - Earnings per share growth rate in current year|Expected earnings per share growth for next year Cidara Therapeutics
- sales and revenue indicators:
CDTX - Revenue and Sales Volume|Company Future Sales Volume Cidara Corp|CDTX - Market Cap to Sales Volume|Forward P/S Multiple Cidara Corp
Fundamental company analysis:Cidara (CDTX)
Original product of Cidara Corp

Investors utilize forward multiples to verify market expectations regarding the issuer's fundamental value. This forward EV/Revenue ratio correlates the current share price with the consensus revenue forecast for the coming year. An increase in this metric confirms market confidence in R&D success, despite the uncertainty surrounding the clinical trial outcomes for Cidara Therapeutics (CDTX). However, an excessive inflation of this metric may signal that the asset is overbought ahead of a potential correction.

Key competitors

Forward P/S Multiple GILD (Gilead Sciences)|NVAX - Forward Price-to-Revenue Multiple|CureVac Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Valneva Vaccines VALN|VIR: Forward P/S Multiple|Market Cap to Projected Revenue SIGA|EBS (Emergent BioSolutions Inc.) - Forward P/S Multiple|Forward P/S Multiple Atea Pharma|Price-to-Projected Revenue Ratio Invivyd, Inc. (IVVD)|ENTA (Enanta Pharmaceuticals, Inc) - Forward Price to Sales|Forward P/S Multiple INO (Inovio Pharmaceuticals)|Forward P/S Multiple hillevax.com HLVX|KLRS: Forward Price-to-Revenue Multiple|Forward Price to Sales DYAI (Dyadic International)|NNVC (nanoviricides.com) - Forward Price-to-Revenue Multiple|TLPH: Price to Expected Revenue Ratio|COCP (Cocrystal Pharma, Inc.) - Forward P/S Multiple|TRAW: Forward Price to Sales|Forward P/S Multiple DWTX|QLGN - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio AlloVir ALVR|Forward Price to Sales VBIV|Virios - Forward P/S Multiple|VXRT - Forward P/S Multiple